Physician profile
Chaewon Song
NPI 1972589687
$21,036.12
in general payments reported to CMS, 2019-2025
53 companies · $2,099 in 2025
The $2,099 reported for 2025 was more than what 94% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,671 · 2020: $2,914 · 2021: $4,116 · 2022: $3,205 · 2023: $2,697 · 2024: $2,334 · 2025: $2,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,057 · Education: $73.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,056.72 |
| Education | $73.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,341.59 | 2019-2025 | Linzess, Viberzi, Creon |
| Novo Nordisk INC | $1,898.79 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $1,590.32 | 2019-2025 | |
| Lilly USA, LLC | $1,310.40 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $1,042.93 | 2019-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $1,016.95 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $939.83 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $838.73 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Astellas Pharma US INC | $824.59 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $779.51 | 2019-2025 | Jardiance |
| Aimmune Therapeutics, INC. | $754.77 | 2024-2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $708.39 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $619.24 | 2019-2025 | Rexulti |
| Fresenius USA Marketing, INC. | $602.16 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Amarin Pharma, INC. | $597.97 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaewon Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.